BACKGROUND: Through mediation of estrogen receptors, estradiol has been shown to have both carcinogenic and anti-carcinogenic effects on the prostate. We performed a population-based case-control study to investigate variants in estrogen-related genes ESR1, ESR2, CYP19A1, CYP1A1, and CYP1B1 and the potential association with risk of prostate cancer (PCa). MATERIALS AND METHODS: We evaluated PCa risk conferred by 73 single nucleotide polymorphisms in 1,304 incident PCa cases and 1,266 age-matched controls. Analysis included stratification by clinical features and assessment of environmental modifiers. RESULTS: There was evidence of altered risk of developing PCa for variants in ESR1, CYP1A1, and CYP1B1, however, only CYP1B1 rs1056836 retained significance after adjustment for multiple comparisons. An association with risk for more aggressive PCa was observed for variants in ESR1, ESR2, and CYP19A1, but none was significant after adjustment for multiple comparisons. There was no effect modification by obesity. CONCLUSIONS: Germline genetic variation of these estrogen pathway genes may contribute to risk of PCa. Additional studies to validate these results and examine the functional consequence of validated variants are warranted.
BACKGROUND: Through mediation of estrogen receptors, estradiol has been shown to have both carcinogenic and anti-carcinogenic effects on the prostate. We performed a population-based case-control study to investigate variants in estrogen-related genes ESR1, ESR2, CYP19A1, CYP1A1, and CYP1B1 and the potential association with risk of prostate cancer (PCa). MATERIALS AND METHODS: We evaluated PCa risk conferred by 73 single nucleotide polymorphisms in 1,304 incident PCa cases and 1,266 age-matched controls. Analysis included stratification by clinical features and assessment of environmental modifiers. RESULTS: There was evidence of altered risk of developing PCa for variants in ESR1, CYP1A1, and CYP1B1, however, only CYP1B1rs1056836 retained significance after adjustment for multiple comparisons. An association with risk for more aggressive PCa was observed for variants in ESR1, ESR2, and CYP19A1, but none was significant after adjustment for multiple comparisons. There was no effect modification by obesity. CONCLUSIONS: Germline genetic variation of these estrogen pathway genes may contribute to risk of PCa. Additional studies to validate these results and examine the functional consequence of validated variants are warranted.
Authors: Sonja I Berndt; Nilanjan Chatterjee; Wen-Yi Huang; Stephen J Chanock; Robert Welch; E David Crawford; Richard B Hayes Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-01 Impact factor: 4.254
Authors: Ilir Agalliu; Claudia A Salinas; Philip D Hansten; Elaine A Ostrander; Janet L Stanford Journal: Am J Epidemiol Date: 2008-06-12 Impact factor: 4.897
Authors: Meredith Yeager; Nick Orr; Richard B Hayes; Kevin B Jacobs; Peter Kraft; Sholom Wacholder; Mark J Minichiello; Paul Fearnhead; Kai Yu; Nilanjan Chatterjee; Zhaoming Wang; Robert Welch; Brian J Staats; Eugenia E Calle; Heather Spencer Feigelson; Michael J Thun; Carmen Rodriguez; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Edward Giovannucci; Walter C Willett; Geraldine Cancel-Tassin; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; Edward P Gelmann; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert Hoover; David J Hunter; Stephen J Chanock; Gilles Thomas Journal: Nat Genet Date: 2007-04-01 Impact factor: 38.330
Authors: Julie M Cunningham; Scott J Hebbring; Shannon K McDonnell; Mine S Cicek; G Bryce Christensen; Liang Wang; Steven J Jacobsen; James R Cerhan; Michael L Blute; Daniel J Schaid; Stephen N Thibodeau Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-05 Impact factor: 4.254
Authors: Yen-Ching Chen; Peter Kraft; Philip Bretsky; Shamika Ketkar; David J Hunter; Demetrius Albanes; David Altshuler; Gerald Andriole; Christine D Berg; Heiner Boeing; Noel Burtt; Bas Bueno-de-Mesquita; Howard Cann; Federico Canzian; Stephen Chanock; Alison Dunning; Heather S Feigelson; Matthew Freedman; J Michael Gaziano; Edward Giovannucci; Maria-Jose Sánchez; Christopher A Haiman; Göran Hallmans; Richard B Hayes; Brian E Henderson; Joel Hirschhorn; Rudolf Kaaks; Timothy J Key; Laurence N Kolonel; Loic LeMarchand; Jing Ma; Kim Overvad; Domenico Palli; Paul Pharaoh; Malcolm Pike; Eliot Riboli; Carmen Rodriguez; V Wendy Setiawan; Meir Stampfer; Daniel O Stram; Gilles Thomas; Michael J Thun; Ruth C Travis; Jarmo Virtamo; Antonia Trichopoulou; Sholom Wacholder; Stephanie J Weinstein Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-10 Impact factor: 4.254
Authors: Jana Jurečeková; Eva Babušíková; Monika Kmeťová; Ján Kliment; Dušan Dobrota Journal: J Cancer Res Clin Oncol Date: 2015-04-01 Impact factor: 4.553
Authors: Li Tang; Mary E Platek; Song Yao; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Yue Wu; Elizabeth A Platz; Marian L Neuhouser; Frank Z Stanczyk; Juergen K V Reichardt; Regina M Santella; Ann Hsing; William D Figg; Scott M Lippman; Ian M Thompson; Christine B Ambrosone Journal: Carcinogenesis Date: 2018-02-09 Impact factor: 4.944
Authors: Kyo Chul Koo; Young Eun Yoon; Koon Ho Rha; Byung Ha Chung; Seung Choul Yang; Sung Joon Hong Journal: Int Urol Nephrol Date: 2014-05-10 Impact factor: 2.370